Fig. 1

TP-0903 treatment inhibits AXL signaling and reduces IBC cell migration and mammosphere formation in vitro and tumor growth in vivo. A TP-0903 reduced phospho-AXL and total AXL protein expression in SUM149 and BCX010 IBC cells as determined using Western blotting. B TP-0903 reduced SUM149 and BCX010 cell migration as tested using transwell migration assay. The mean number of migrated cells was determined for the 4 vehicle replicates in SUM149 and 3 vehicle replicates in BCX010. For each sample (12 each for SUM149 and 9 each for BCX010), the number of migrated cells, relative to the mean in the vehicle group, was plotted as a percentage (“% of vehicle”). C TP-0903 reduced primary and secondary mammosphere formation of SUM149 and BCX010 cells as determined using a surrogate mammosphere formation assay. D Tumor growth curves for vehicle- and TP-0903–treated groups in human IBC xenograft mouse models. TP-0903 decreased SUM149 and BCX010 tumor volumes in mice. SUM149 xenograft model: n = 12 mice; BCX010 xenograft model: n = 14 mice. Data were summarized as means ± SD in B and C and means ± SEM in D. One-way analysis of variance followed by Dunnett’s multiple comparison test (B and C) or 2-tailed Student t test (D) was used to calculate P values. *P < 0.05; **P < 0.01